I Wasted $1.2 Million on Medical Equipment: The Procurement Mistakes Still Costing Hospitals in 2025

Here's my unabashed opinion: the cheapest medical equipment is usually the most expensive thing a hospital can buy. I know that sounds like a line from a vendor brochure, but I have the receipts—literally, a folder of purchase orders and service invoices that taught me everything I'm about to tell you.

I'm a capital equipment buyer for a regional hospital network. I've been handling equipment orders for eight years, and I've personally made (and documented) 11 significant purchasing mistakes, totaling roughly $1.2 million in wasted budget. Now I maintain our team's procurement checklist. I update it every time a vendor teaches me something new, which happens more often than I'd like to admit.

The Question Everyone Asks Is the Wrong One

Most buyers focus on per-unit pricing and completely miss installation, training, service contracts, and unplanned downtime—which, in my experience, can add 30 to 50 percent to the real cost. The question everyone asks is, "What's your best price?" The question they should ask is, "What does this system cost per usable procedure over its full life?"

I built that second calculation after my first disaster in 2017, and since then it's caught 47 potential errors in the past 18 months. The calculation is simple: acquisition cost plus install, training hours, planned service, consumable replacements, and a line item I call the "downtime tax." The last one has been our most valuable number.

The Stryker Inari Medical Acquisition 2025: What It Actually Signals

Let's anchor this in something concrete. According to Stryker's official newsroom announcement on January 6, 2025, Stryker agreed to acquire Inari Medical for approximately $4.9 billion, with the deal expected to close in the first quarter of 2025. Inari makes thrombectomy devices for venous disease—clot-retrieval systems like ClotTriever and FlowTriever used to treat deep vein thrombosis and pulmonary embolism.

Why should a hospital buyer care? Because a pulmonary embolism patient treated early in the emergency department can avoid the ICU, avoid a week-long stay, and free up resources for the next patient. That's efficiency as a hardware promise. And when you look at Stryker's recent news from 2024—the Care.ai acquisition in September, the steady expansion of Mako robotic placements, and full-year 2024 net sales of approximately $22.6 billion reported in January 2025—the pattern is consistent. The device companies winning the next decade are the ones selling ways to compress the cost of a care episode, not just ways to replace a worn-out instrument.

And with payers pushing more reimbursement risk onto hospitals, efficiency isn't a nice-to-have. It's the difference between a department that breaks even and one that gets cut.

The C-Arm System That Made Me Build a Spreadsheet

Back in 2017—my first year—I approved a purchase order for a C-arm system priced about $10,000 below the competing bid. I remember feeling proud of that negotiation. What I didn't check: how many certified service engineers were actually within driving distance.

The answer turned out to be one engineer, three states away. When the tube arm's calibration drifted in September 2022, the fix required a service visit—actually, not an emergency visit, because our contract wasn't written for that. A scheduled visit. It took three business days to get on the books. Fourteen surgical cases had to be rescheduled.

The service call itself was $3,200. The downtime cost—extra OR staff standby, rescheduled physician time, lost surgical volume—was perhaps four times that. I'm not 100% sure of the exact number, because the accounting department and I measured it differently, but "expensive" was not a matter of debate.

The point is simple: the C-arm was just metal and electronics. The real product was the service ecosystem around it. (Should mention: the vendor's brochure said "nationwide service," which technically meant one person per state.) Now, our imaging purchases—including Stryker's mobile imaging options like the Airo TruCT—get evaluated on total cost per usable procedure, not on list price. The sticker price earns the right to enter the conversation, and then it stops talking.

Power Wheelchairs and the $21,000 Tail

Another mistake I'm happy to confess: the power wheelchair fleet. We ordered 14 power wheelchairs for a long-term care wing, and the unit price was genuinely competitive—about 9 percent under the other bid. I celebrated. Then the real cost walked in.

The batteries started dying at month 16, conveniently just past the vendor's 12-month warranty. Replacement: $1,350 per chair. The charging docks needed $2,100 in repairs. Delivery crating fees appeared that the quote hadn't shown. A $95,200 purchase ended up with a $21,000 tail—and that's before counting the clinical time spent moving patients when chairs wouldn't charge.

I have mixed feelings about this one. On one hand, I've seen premium-priced equipment waste money on features nobody uses. On the other hand, "cheap" only works if you calculate the five-year picture. Part of me wants to consolidate every mobility purchase with one vendor for simplicity. Another part remembers that a single-vendor strategy got us into the battery trap in the first place. I've compromised: we now require every mobility vendor to provide a five-year per-unit cost projection covering batteries, dock compatibility, parts, and technician response time. If a vendor won't put that in writing, that tells me something useful.

Spinal Cord Stimulators: You're Buying Training, Not Just Hardware

Then there's the implant side. We selected a spinal cord stimulator system for our pain program, and the hardware price dominated the review. The twist: much of the real cost was the training and programming ecosystem.

Our pain physicians needed extra training. The vendor's standard package included a set number of training credits—nowhere near enough, as it turned out. Some clinicians learned the programming software by trial and error. When the software platform changed mid-year, one follow-up titration session went badly enough that we had to bring in an outside specialist at $450 an hour.

A surgeon on our committee summed it up better than I ever could:

"The lead is a medical device; the follow-up is a marriage."

I've used that line in every implant contract review since. An implant is not a product; it's an ecosystem of training, software updates, and vendor patience. The question isn't "what's the device cost?" The question is "what does a successful patient outcome cost, including the support system behind it?"

Per FTC business guidance (ftc.gov), marketing claims need to be truthful and substantiated. I've learned to ask for that substantiation in writing—applied to training hours, service coverage, and software support, not just to the clinical evidence.

Let Me Answer the Objection You're Forming

I know what some of you are thinking: "Easy for you to say. My department is on a shoestring budget. We have to take the lowest bid." I've made that argument to my own CFO, and I respect it.

But spending money efficiently doesn't mean minimizing purchase price. It means minimizing cost per good outcome. A $6,800 power wheelchair that strands a patient at month 16 is not cheaper than an $8,400 chair with a real service contract. A C-arm that saves $10,000 on paper but darkens an OR for three days is a bad deal at any price. Put another way: the most expensive words in procurement are "it seemed cheaper at the time."

I'm not saying every premium product justifies its premium. In my opinion, some don't. What I am saying is that a significant purchase decision made without a total-cost model isn't frugal—it's a gamble. And I've bought enough losing tickets to know the odds.

The Bottom Line

Eight years, 11 documented mistakes, roughly $1.2 million in wasted budget. My opinion hasn't changed through any of it: efficiency is the real competitive advantage in healthcare procurement, and efficiency is measured in cost per outcome, not unit price.

The Stryker Inari Medical acquisition in 2025, and Stryker's broader momentum through 2024, tell me the same story the spreadsheet does—the future belongs to the teams that measure the whole episode. My job now is to make sure our hospital is one of them.

Ask your purchasing team for the total-cost calculation on the last five capital purchases. If it doesn't exist, you might be sitting on your own $1.2 million of hidden waste. Find it. Write it down. And if you're braver than I was, share it with the rest of us.